Quintiles will help Barcelona-based Almirall bring its new respiratory drugs to market in the United Kingdom.
Under the long-term partnership announced Monday morning, the first drug will treat chronic obstructive pulmonary disease treatment (COPD). The treatment was approved by the European Commission in late May.
Quintiles is a Durham-based contract research organization. It conducted part of the clinical study of the COPD treatment and also helps Almirall bring products to market in multiple European countries.
No financial terms of the deal were disclosed.